Impact of Laparoscopic Splenectomy and Azygoportal Disconnection on Immune Function in Adults with Liver Cirrhosis

What this Trial Is About

Researchers are evaluating changes in immune function after laparoscopic splenectomy and azygoportal disconnection in patients with liver cirrhosis. The study aims to determine whether this surgical treatment can improve immune indicators and patient prognosis following surgery. This research focuses on patients with cirrhosis complicated by splenomegaly and gastroesophageal variceal bleeding. Participants undergo laparoscopic splenectomy and azygoportal disconnection performed by the same surgical team. After surgery, a unified treatment plan including medications and other therapies is provided. Immune function is monitored by measuring leukocytes, neutrophils, lymphocytes, monocytes, and immune cell markers such as CD4, CD8, CD19, and CD20 at multiple time points before surgery, and at 3, 6, 12, and 24 months post-surgery. During the study, patients provide general health information and receive nursing care from the same team. Follow-up visits include blood tests to assess immune cell counts and ratios. Researchers track these immune markers over two years to understand changes after surgery and treatment. The study began in March 2022 and will conclude in July 2025, with safety and immune function closely monitored throughout.

The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on the Immune Function for Cirrhosis Patients